PF-Atlas › Treatments › Macrophage M2 Reprogramming
Macrophage M2 Reprogramming
LNP-mRNA IRF4/STAT6/KLF4 forces pro-regenerative macrophage state
Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Preclinical
Evidence level
Level 3 (Cross-domain)
Mechanism class
LNP-mRNA IRF4/STAT6/KLF4 forces pro-regenerative macrophage state
Timeline
3-5 years
Risk profile
Medium
Developer
Multiple
Key researchers
J. Godwin
Overview
Axolotl macrophages are obligatory for regeneration. Human alveolar macrophages stuck in SPP1+ pro-fibrotic state. Novel cross-species insight.
How Macrophage M2 Reprogramming fits into IPF treatment
Macrophage M2 Reprogramming is classified as Level 3 (Cross-domain) at the Preclinical stage. Explore how it compares to other options and where it sits in the development pipeline:
Other IPF treatments
Medical disclaimer. This page summarizes published research and PF-Atlas model output about Macrophage M2 Reprogramming for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.